Fri, Aug 22, 2014, 9:58 AM EDT - U.S. Markets close in 6 hrs 2 mins


% | $
Quotes you view appear here for quick access.

Dynavax Technologies Corporation Message Board

bigredkachina 15 posts  |  Last Activity: Aug 8, 2014 10:34 AM Member since: Aug 12, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Nothing really new on conference call. The next few months will be interesting. I noticed short interest is down to 3.6% from 4.13% but short interest is not what is driving pps.

    A couple of things were clarified for me listening to Trov execs answer the questions from Maxim. Overall Trovagene has to build its case thoroughly on multiple fronts and that there is an abundance of interest across the board in their approach, to the point that they turn down more requests than they service and that those partnerships they participate in are laser focused to service their strategy for the divergent needs their technology addresses.

    Also, they are building an automated system that will service a wide range of genomic queries with one pass. So, no one-off assays are being provided which I think confuses many here who thought the one-offs for KRAS, BRAF, HPV etal. would be generating revenue by now are to be bundled into the automated pass.

    They also seemed to relish the idea that FDA was considering regulating some LDT activity.

    All in all it seems to me that they are still making progress towards commercialization. I get the sense that the cancer clinics' personnel conducting the studies are excited about the concept and promoting from within, even to the point of insisting that it be exported to certain of their colleagues as was the case regarding the migration of the Erdheim Chester BRAF from MD Anderson to Sloan Kettering.

    All that being said, I thing pps will hover above 3 and will be driven by catalysts until concrete deals are consummated and profits begin to appear on the bottom line which I'm guessing 2nd qtr 2015.

  • bigredkachina by bigredkachina Aug 6, 2014 11:00 AM Flag

    Modest profit. Bought in the .08's after the fall from .19 Too many shares, not enough profit from royalties to go around. Good luck.

  • Reply to

    Something's up. 3.51 AH

    by bigredkachina Jul 29, 2014 4:59 PM
    bigredkachina bigredkachina Jul 30, 2014 8:03 AM Flag

    Not to quibble but it was 1650, not 1350. Any break in the recent downward pressure is appreciated, if not significant. My last buy was at 3.15 Been in this one for nearly 2 years, started buying when it was in the 2's. Now have nearly 20k shares cost basis at 3.30. I know. Should have sold when 8+ but thought it would be in the teens by now. With their technology, Affordable Care Act passage, I thought it would be a no-brainer cost cutter for the healthcare/insurance industry. Apparently it is way easy to manipulate with no revenue on the books. Add to that the whole bioscience space has generally been sold off since Feb. and you have what we have here. Here's to better days ahead.

  • bigredkachina by bigredkachina Jul 29, 2014 4:59 PM Flag

    Must be some news lurking somewhere that isn't available to us peons yet.

  • bigredkachina by bigredkachina Jul 28, 2014 4:53 PM Flag

    Mademoiselle, you have the choice. You can pee in a cup or partake in zee colposcopically-directed punch biopsy. Which do you prefer?

    Human papillomavirus (HPV) testing in urine offers a convenient approach for cervical cancer screening but has previously suffered from limited clinical sensitivity.
    We evaluated clinical performance of the prototype Trovagene HPV test, a novel polymerase chain reaction assay that targets the E1 region of the HPV genome and detects and amplifies short fragments of cell-free HPV DNA in urine.
    We conducted a pilot study among 72 women referred to colposcopy following abnormal screening. Participants provided a urine sample prior to clinician-collected cervical sampling and colposcopically-directed punch biopsy. Trovagene HPV test results on urine samples were compared with cervical and urine testing by Linear Array HPV Genotyping Test (LA-HPV) for detection of histologically-confirmed cervical precancerous lesions.
    There was high concordance between urine samples tested by the Trovagene HPV test and corresponding cervical (87.5%) and urine (81.9%) samples tested by LA-HPV. The Trovagene HPV test had high sensitivity (92.3% for detecting CIN2/3, and 100% for CIN3), comparable to LA-HPV testing on cervical samples (96.0% and 100%, respectively), and higher than LA-HPV testing on urine samples (80.8% and 90.0%, respectively). In this referral population, the specificity of the Trovagene urine HPV test was non-significantly lower (29% for CIN2/3 and 25% for CIN3) than corresponding estimates of LA-HPV testing on cervical (36% and 28%, respectively) and urine (42% and 38%, respectively) samples.
    This pilot study suggests that the Trovagene HPV test has high sensitivity for urine-based detection of cervical precancer and merits evaluation in larger studies.
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

  • bigredkachina by bigredkachina Jul 23, 2014 8:40 AM Flag

    Experian is a 1 trillion dollar market cap corp. Surely there is something in it for BKYI. Should see some movement in pps as news gets out.

  • bigredkachina by bigredkachina Jul 22, 2014 3:23 PM Flag

    It isn't short selling because short interest is down to 4.13% from 4.19%. Every move up countered with dump. Limitless shares to meet lower and lower bid.

  • Applications: Mobile Devices, Government, Defense, Healthcare, Commercial Security and Banking & Finance.

    Expected market: 15 billion.

  • bigredkachina by bigredkachina Jun 16, 2014 3:42 PM Flag

    Just bought another wad of EGHT this morning. It is oversold here and will be back at 10 before you know it.

  • Reply to

    Sold Shares

    by bigswan1979 Jun 15, 2014 9:42 AM
    bigredkachina bigredkachina Jun 16, 2014 3:31 PM Flag

    I must say you have exquisite timing Mr. Swan. Name of the game is buy low sell high, but you know that don't you? Don't you?

  • Reply to

    Where are all the KAD?

    by mannchris686 Jun 11, 2014 10:09 AM
    bigredkachina bigredkachina Jun 11, 2014 1:27 PM Flag

    Here's a suggestion for you putz. Instead of contacting Scottrade for certificates why don't you use some of those counterfeit shares you guys are bandying about here to wipe your #$%$ with? Better get a big handful tho, as you are so full of #$%$ you will need a couple thousand just to take a dump.

  • Reply to

    Where are all the KAD?

    by mannchris686 Jun 11, 2014 10:09 AM
    bigredkachina bigredkachina Jun 11, 2014 10:29 AM Flag

    So, the price dips and the Village Idiot is back squirting all over herself. What else is new.

  • Reply to

    Price Action

    by mannchris686 Jun 3, 2014 10:21 AM
    bigredkachina bigredkachina Jun 3, 2014 4:20 PM Flag

    I see Henny Penny village idiot is back at it again. One day the sky WILL fall but it won't be here, putz.

  • That has a nice ring to it. Can't decide whether I like the multi-disciplinary part or clinical consensus part better. In any event it proves that TROV technology is the go-to solution for monitoring BRAF V600E mutations in Erdheim-Chester disease. Yeah, I know it is a niche area compared to the overall cancer arena, but TROV was 100% for all patients and it is an area where biopsies are impractical much of the time. Study done at MD Anderson, guidelines published at Sloan-Kettering.

    So, the beat-down continues. I guess TROV is easy prey for the sharks right now, seeing as they haven't had any significant revenues to date. Currently one has to be satisfied that the technology is being validated and at some point in time revenues will follow.

  • Only peg left is earnings shortfall and that will diminish as earnings from new contracts start hitting the books this fall and beyond. I see 2+ here by Labor Day.

1.410.00(0.00%)9:57 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.